ORIC Pharmaceuticals Selects Rinzimetostat Dose for Phase 3 Prostate Cancer Trial

Event summary

  • ORIC Pharmaceuticals selected 400 mg once daily as the recommended Phase 3 dose for rinzimetostat in combination with darolutamide.
  • Landmark 5-month radiographic progression-free survival (rPFS) of 84% observed in post-abiraterone mCRPC patients.
  • Himalayas-1 Phase 3 trial expected to initiate in 1H 2026, targeting a $7 billion global market.
  • Rinzimetostat demonstrated a significantly cleaner safety profile with mostly Grade 1 or 2 adverse events.

The big picture

ORIC Pharmaceuticals is advancing its lead candidate, rinzimetostat, into a pivotal Phase 3 trial for metastatic castration-resistant prostate cancer (mCRPC), targeting a significant unmet need in the oncology space. The selection of the recommended Phase 3 dose follows promising early data, positioning rinzimetostat as a potential best-in-disease therapy with a favorable safety profile. The upcoming Himalayas-1 trial will be a critical milestone in determining the drug's commercial viability in a competitive landscape dominated by established treatments like Xtandi and Jevtana.

What we're watching

Clinical Efficacy
Whether rinzimetostat's early efficacy signals will translate into statistically significant outcomes in the Phase 3 trial.
Regulatory Pathway
The pace at which the FDA will review the Himalayas-1 trial data, given its alignment with Project Optimus.
Market Penetration
How ORIC will position rinzimetostat against existing therapies in the $7 billion mCRPC market.